Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Strengths
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company is one of the best yield companies with high dividend expectations.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
  • The stock is close to a major daily resistance at USD 70.05, which should be gotten rid of so as to gain new appreciation potential.
  • According to Thomson-Reuters' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • With an enterprise value anticipated at 4.27 times the sales for the current fiscal year, the company turns out to be overvalued.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
GILEAD SCIENCES10.92%80 909
VERTEX PHARMACEUTICALS11.02%42 680
REGENERON PHARMACEUTICALS-14.29%32 744
GENMAB12.51%10 857
SAREPTA THERAPEUTICS INC19.01%8 523
NEUROCRINE BIOSCIENCES, INC..19.03%7 500
BEIGENE LTD--.--%7 219
BLUEBIRD BIO INC20.84%6 748
ARRAY BIOPHARMA INC225.19%6 236
PEPTIDREAM INC26.89%6 139
ASCENDIS PHARMA A/S95.36%6 123
EXELIXIS, INC.8.64%5 915
HUALAN BIOLOGICAL ENGINEERI..--.--%5 814
BIOCON LTD-20.66%4 730
ARGEN-X42.61%4 699
TONGHUA DONGBAO PHARMACEUTI..0.65%4 300
More Results
Financials ($)
Sales 2019 22 048 M
EBIT 2019 11 439 M
Net income 2019 6 954 M
Debt 2019 5 969 M
Yield 2019 3,64%
P/E ratio 2019 12,76
P/E ratio 2020 12,59
EV / Sales 2019 4,27x
EV / Sales 2020 3,89x
Capitalization 88 220 M
Upcoming event on GILEAD SCIENCES
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes